VolitionRX Ltd’s filing revealed that its Chief Scientific Officer Micallef Jacob Vincent acquired Company’s shares for reported $21500.0 on May 19 ’25. In the deal valued at $0.43 per share,50,000 shares were bought. As a result of this transaction, Micallef Jacob Vincent now holds 426,033 shares worth roughly $0.18 million.
Then, Reynolds Cameron John bought 20,000 shares, generating $8,730 in total proceeds. Upon buying the shares at $0.44, the President and CEO now owns 2,319,222 shares.
Before that, Reynolds Cameron John bought 181,818 shares. VolitionRX Ltd shares valued at $100,000 were divested by the President and CEO at a price of $0.55 per share. As a result of the transaction, Reynolds Cameron John now holds 2,299,222 shares, worth roughly $0.97 million.
H.C. Wainwright initiated its VolitionRX Ltd [VNRX] rating to a Buy in a research note published on April 08, 2025; the price target was $2.50. A number of analysts have revised their coverage, including The Benchmark Company’s analysts, who decreased its forecast for the stock in early February from “a Buy” to “a Hold”. Cantor Fitzgerald started covering the stock on March 10, 2021. It rated VNRX as “an Overweight”.
Price Performance Review of VNRX
On Monday, VolitionRX Ltd [AMEX:VNRX] saw its stock fall -2.49% to $0.42. Over the last five days, the stock has lost -15.28%. VolitionRX Ltd shares have fallen nearly -30.13% since the year began. Nevertheless, the stocks have fallen -46.73% over the past one year. While a 52-week high of $0.90 was reached on 01/10/25, a 52-week low of $0.42 was recorded on 05/19/25.
How much short interest is there in VolitionRX Ltd?
A steep rise in short interest was recorded in VolitionRX Ltd stocks on 2025-04-30, dropping by -0.31 million shares to a total of 0.38 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 0.69 million shares. There was a decline of -80.42%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on May 16, 2018 when Maxim Group began covering the stock and recommended ‘”a Buy”‘ rating along with a $6 price target.
